Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.


ATRYS obtains funding from CDTI for research in liquid biopsy in prostate cancer

July 29, 2019

Madrid, July 29, 2019.

ATRYS HEALTH (“ATRYS”) has obtained the support of the CDTI for the financing of its research project SURVEPROST, througth the call for UNILATERAL international collaboration projects. In this collaboration, ATRYS joins its R&D efforts with DINÁMICA (GRUPO SURA), a leading diagnostic company in Colombia, to develop a molecular firm in liquid biopsy for active surveillance in prostate cancer, SURVEPROST.